245 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author김용희-
dc.date.accessioned2017-08-03T05:14:47Z-
dc.date.available2017-08-03T05:14:47Z-
dc.date.issued2015-10-
dc.identifier.citationJOURNAL OF CONTROLLED RELEASE, v. 215, Page. 82-90en_US
dc.identifier.issn0168-3659-
dc.identifier.issn1873-4995-
dc.identifier.urihttp://www.sciencedirect.com/science/article/pii/S0168365915300286?via%3Dihub-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/28249-
dc.description.abstractEffective intracellular level of a platinumanti-cancer drug, cisplatin, following repeated injections can be decreased either by the active efflux via ATP pump or by interactions with glutathione and metallothionein. Cisplatin in cytoplasm preferably binds to cysteine-rich proteins such as glutathione and metallothionein (MT). Detoxification of cisplatin by intracellular thiol-containing proteins has been considered to be major hurdles to overcome. The short hairpin RNA targeting MT (shMT) was tested to down-regulate MT and recover cisplatin resistance. A reducible polymer, poly(oligo-D-arginine) (rPOA), formed stable complex with shMT and demonstrated superior transfection efficiency. Efficient transfection of shMT/rPOA oligo-peptoplexes was found to significantly inhibit MT overexpression, resulting in 45% decrease of cell viability compared to the cisplatin alone group. This decrease was mediated by the synergistic effect of shMT/rPOA oligo-peptoplex and cisplatin. Co-administration of shMT/rPOA oligo-peptoplex and cisplatin in in vivo tumor model showed noticeable tumor-suppressing effect by inducing reversal of cisplatin resistance following effective intracellular delivery of shMT by rPOA. Combination therapy through co-administration of shMT/rPOA oligo-peptoplex and cisplatin was found to effectively reverse cisplatin resistance by RNA interference and consequently improve anti-cancer activity of cisplatin. (C) 2015 Elsevier B.V. All rights reserved.en_US
dc.description.sponsorshipThis work was partially supported by grants from the National Research Foundation of Korea (2014049587), the Brain Korea 21 plus program (22A20130011095), and the Korean Health Technology R&D project through the Ministry of Health &Welfare (HI13C-1938-010014).en_US
dc.language.isoenen_US
dc.publisherELSEVIER SCIENCE BVen_US
dc.subjectCisplatin resistanceen_US
dc.subjectRNA interferenceen_US
dc.subjectMetallothioneinen_US
dc.subjectCombination therapyen_US
dc.titleInhibition of cisplatin-resistance by RNA interference targeting metallothionein using reducible oligo-peptoplexen_US
dc.typeArticleen_US
dc.relation.volume215-
dc.identifier.doi10.1016/j.jconrel.2015.07.015-
dc.relation.page82-90-
dc.relation.journalJOURNAL OF CONTROLLED RELEASE-
dc.contributor.googleauthorLee, Jong-Hwan-
dc.contributor.googleauthorChae, Ji-Won-
dc.contributor.googleauthorKim, Jang Kyoung-
dc.contributor.googleauthorKim, Hyung Jin-
dc.contributor.googleauthorChung, Jee Young-
dc.contributor.googleauthorKim, Yong-Hee-
dc.relation.code2015002880-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF ENGINEERING[S]-
dc.sector.departmentDEPARTMENT OF BIOENGINEERING-
dc.identifier.pidyongheekim-
Appears in Collections:
COLLEGE OF ENGINEERING[S](공과대학) > BIOENGINEERING(생명공학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE